GR3033695T3 - Gene therapy for cell proliferative diseases. - Google Patents

Gene therapy for cell proliferative diseases.

Info

Publication number
GR3033695T3
GR3033695T3 GR20000401385T GR20000401385T GR3033695T3 GR 3033695 T3 GR3033695 T3 GR 3033695T3 GR 20000401385 T GR20000401385 T GR 20000401385T GR 20000401385 T GR20000401385 T GR 20000401385T GR 3033695 T3 GR3033695 T3 GR 3033695T3
Authority
GR
Greece
Prior art keywords
proliferative diseases
gene therapy
cell proliferative
dna
regulatory gene
Prior art date
Application number
GR20000401385T
Other languages
English (en)
Inventor
Yuen Kai Fung
Alan Linn Murphree
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of GR3033695T3 publication Critical patent/GR3033695T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR20000401385T 1990-04-10 2000-06-15 Gene therapy for cell proliferative diseases. GR3033695T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50741790A 1990-04-10 1990-04-10
PCT/US1991/002478 WO1991015580A1 (en) 1990-04-10 1991-04-10 Gene therapy for cell proliferative diseases

Publications (1)

Publication Number Publication Date
GR3033695T3 true GR3033695T3 (en) 2000-10-31

Family

ID=24018569

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000401385T GR3033695T3 (en) 1990-04-10 2000-06-15 Gene therapy for cell proliferative diseases.

Country Status (18)

Country Link
EP (2) EP0527804B1 (el)
JP (1) JPH05507067A (el)
KR (1) KR100304033B1 (el)
CN (1) CN1057121C (el)
AT (1) ATE190652T1 (el)
AU (3) AU7750191A (el)
CA (1) CA2079903A1 (el)
DE (1) DE69132047T2 (el)
DK (1) DK0527804T3 (el)
ES (1) ES2143463T3 (el)
FI (1) FI924574A0 (el)
GR (1) GR3033695T3 (el)
IE (2) IE911115A1 (el)
IL (1) IL97774A0 (el)
NO (1) NO923917L (el)
PT (1) PT97316B (el)
WO (1) WO1991015580A1 (el)
ZA (1) ZA912491B (el)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
US5532220A (en) * 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5262321A (en) * 1991-05-31 1993-11-16 Dana-Farber Cancer Institute DNA encoding p107 tumor suppressor
DE69232722T2 (de) * 1991-08-23 2002-12-05 Univ Nebraska Lincoln Board Of Verfahren und zusammensetzungen für zelluläre reprogrammierung
US6348327B1 (en) 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5302706A (en) * 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US6420172B1 (en) * 1992-04-20 2002-07-16 Tib Company, Llc Method for inducing tumor immunity
WO1993023569A1 (en) * 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US5496698A (en) * 1992-08-26 1996-03-05 Ribozyme Pharmaceuticals, Inc. Method of isolating ribozyme targets
US5610052A (en) * 1992-08-26 1997-03-11 Ribozyme Pharmaceuticals Inc. Enzymatic RNA with activity to ras
US5622854A (en) * 1992-05-14 1997-04-22 Ribozyme Pharmaceuticals Inc. Method and reagent for inhibiting T-cell leukemia virus replication
US6258585B1 (en) 1992-05-14 2001-07-10 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting influenza virus replication
US5750390A (en) * 1992-08-26 1998-05-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
US6492512B1 (en) 1992-08-26 2002-12-10 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5972699A (en) * 1992-05-14 1999-10-26 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting herpes simplex virus replication
US5525468A (en) * 1992-05-14 1996-06-11 Ribozyme Pharmaceuticals, Inc. Assay for Ribozyme target site
US5989906A (en) * 1992-05-14 1999-11-23 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting P-glycoprotein (mdr-1-gene)
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
JPH07509133A (ja) * 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US6544755B1 (en) 1992-08-26 2003-04-08 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases by expression of the c-Myc gene
US5599704A (en) * 1992-08-26 1997-02-04 Ribozyme Pharmaceuticals, Inc. ErbB2/neu targeted ribozymes
EP0672137A1 (en) * 1992-09-18 1995-09-20 CANJI, Inc. Gene therapy by retroviral vector with tumor suppressive gene
DE69334238D1 (de) 1992-09-25 2008-09-25 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
WO1994011506A1 (en) 1992-11-18 1994-05-26 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
US5616490A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. Ribozymes targeted to TNF-α RNA
US5658780A (en) * 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
US5811300A (en) * 1992-12-07 1998-09-22 Ribozyme Pharmaceuticals, Inc. TNF-α ribozymes
US5837542A (en) * 1992-12-07 1998-11-17 Ribozyme Pharmaceuticals, Inc. Intercellular adhesion molecule-1 (ICAM-1) ribozymes
US5616488A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
US5612215A (en) * 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
AU5961094A (en) * 1992-12-31 1994-08-15 Texas Biotechnology Corporation Antisense molecules directed against a platelet derived growth factor receptor related gene
US5639655A (en) * 1993-01-19 1997-06-17 Ribozyme Pharmaceuticals, Inc. PML-RARA targeted ribozymes
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
EP0714436B1 (en) * 1993-07-19 2003-05-07 Gen-Probe Incorporated Oligonucleotides with activity against human immunodeficiency virus
US5739309A (en) * 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
AU7983294A (en) * 1993-10-19 1995-05-08 Regents Of The University Of Michigan, The P53-mediated apoptosis
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
EP0750503A4 (en) * 1994-03-07 1999-07-21 Immusol Inc RIBOZYME-BASED THERAPY TO TREAT RESTENOSIS
US5834440A (en) * 1994-03-07 1998-11-10 Immusol Incorporated Ribozyme therapy for the inhibition of restenosis
WO1995024477A1 (en) * 1994-03-08 1995-09-14 City Of Hope Human papillomavirus targeted ribozymes
US6103890A (en) * 1994-05-18 2000-08-15 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids that cleave C-fos
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
AU4502096A (en) * 1994-11-11 1996-06-06 Arch Development Corporation A process of inhibiting non-neoplastic pathological cell proliferation
US5869040A (en) * 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
JP2000510449A (ja) * 1996-04-10 2000-08-15 南カリフォルニア大学 増殖性硝子体網膜症に対する遺伝子治療
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
WO1998001148A1 (en) 1996-07-09 1998-01-15 President And Fellows Of Harvard College Use of papillomavirus e2 protein in treating papillomavirus-infected cells and compositions containing the protein
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
EP0925074A4 (en) 1996-09-06 2002-04-17 Univ Columbia REVERSE OF A CANCER PHENOTYPE BY EXPRESSION INHIBITING PROSTATATUM-INDUCING GENES
US6057156A (en) * 1997-01-31 2000-05-02 Robozyme Pharmaceuticals, Inc. Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
KR20010072475A (ko) * 1998-08-13 2001-07-31 추후제출 재발협착증을 치료하기 위한 ｄｎａ자임 및 치료 방법
WO2000023624A1 (en) * 1998-10-22 2000-04-27 Duke University Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
WO2001030362A2 (en) * 1999-10-26 2001-05-03 Immusol Incorporated Ribozyme therapy for the treatment of proliferative skin and eye diseases
EP1366058B1 (en) 2001-02-09 2011-01-26 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
WO2004097020A2 (en) * 2003-04-25 2004-11-11 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase gene expression
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2006128063A2 (en) * 2005-05-25 2006-11-30 Irm Llc Methods and compositions for inhibiting glioma growth
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
ATE168135T1 (de) * 1988-01-21 1998-07-15 Massachusetts Eye & Ear Infirm Diagnose von retinoblastoma
WO1989012687A1 (en) * 1988-06-16 1989-12-28 La Jolla Cancer Research Foundation Retinoic acid receptor
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
CA2006008C (en) * 1988-12-20 2000-02-15 Donald J. Kessler Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
ATE170561T1 (de) * 1990-03-14 1998-09-15 Washington Res Found Methode und zusammensetzungen zur behandlung von bösartigen entartungen, die in zusammenhang mit einer proteinkinase stehen
AU7152191A (en) * 1990-06-07 1991-12-31 City Of Hope Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US5262321A (en) * 1991-05-31 1993-11-16 Dana-Farber Cancer Institute DNA encoding p107 tumor suppressor

Also Published As

Publication number Publication date
PT97316B (pt) 1998-08-31
KR937000652A (ko) 1993-03-15
IL97774A0 (en) 1992-06-21
NO923917L (no) 1992-12-01
WO1991015580A1 (en) 1991-10-17
DE69132047T2 (de) 2000-07-13
ATE190652T1 (de) 2000-04-15
DK0527804T3 (da) 2000-06-05
EP0527804A4 (en) 1993-07-14
AU9048698A (en) 1999-01-14
CN1056427A (zh) 1991-11-27
DE69132047D1 (de) 2000-04-20
AU7750191A (en) 1991-10-30
ZA912491B (en) 1993-02-24
EP0960941A1 (en) 1999-12-01
JPH05507067A (ja) 1993-10-14
KR100304033B1 (ko) 2001-12-15
PT97316A (pt) 1991-12-31
ES2143463T3 (es) 2000-05-16
CA2079903A1 (en) 1991-10-11
FI924574A (fi) 1992-10-09
FI924574A0 (fi) 1992-10-09
EP0527804B1 (en) 2000-03-15
CN1057121C (zh) 2000-10-04
AU3319495A (en) 1996-03-07
NO923917D0 (no) 1992-10-08
IE911115A1 (en) 1991-10-23
EP0527804A1 (en) 1993-02-24
IE20010427A1 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
EP0527804A4 (en) Gene therapy for cell proliferative diseases
HUT38125A (en) Process for preparing lymphokines /cytotoxic factors/ and pharmaceutical compositions containing such active substance
AU566348B2 (en) Yeast hybrid vectors and their use for the production of polypeptides
DE69433371D1 (de) Polypeptid, fähig zur Inhibierung der Bindung zwischen menschliches IL-6 und dessen Rezeptor
IL64243A (en) Hybrid human leukocyte interferon type anti-viral polypeptides,their preparation by genetic engineering methods and pharmaceutical compositions containing them
ES2062334T3 (es) Compuestos de 19-nor-vitamina d.
PT76546B (en) Process for preparing functional human urokinase protein
IL74947A (en) Analogs of human gamma interferon having the partial sequence of human gamma interferon and genetic engineering process for the preparation thereof
IL75963A (en) Omega interferon polypeptides of type 1,n-glycosylated derivatives thereof with omega interferon activity,polynucleotide sequences encoding the omega interferon polypeptides,methods for the preparation of the polypeptides and pharmaceutical compositions containing them
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
DE3572441D1 (en) Use of interferon gamma (ifn-gamma) for the production of preparations for treating rheumatic diseases
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
EP0473080A3 (en) Chondromodulin-i protein
ES8300477A1 (es) Procedimiento para la preparacion de una composicion para el tratamiento del cancer